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Abstract
In colorectal cancer, BRAF and KRAS oncogenes are mutated in about 15% and 35% respectively at approximately
the same stage of the adenoma-carcinoma sequence. Since these two mutations rarely coexist, further analysis to
dissect their function of transformation in colon cancer is required. Caco-2 human colon adenocarcinoma cells
were stably transfected with BRAFV600E (Caco-BR cells) or KRASG12V (Caco-K cells) oncogenes. BRAFV600E is more
efficient in transforming Caco-2 cells and altering their morphology. The dominant nature of BRAFV600E is evident
by its ability to render Caco-2 cells tumorigenic in vivo all be it through selective extracellular signal–related kinase
(ERK) 2 phosphorylation and high levels of cyclin D1. As a consequence, the cell cycle distribution of parental cells
is altered and microsatellite instability is introduced. Attenuated ERK activation observed correlated with KSR
downregulation by BRAFV600E without further implications to signaling. Highly activated ERK in case of KRASG12V
(Caco-K cells) leads to mild transformation causing Caco-K cells to express premature senescence-related markers
and acquire growth factor–dependent viability. Interestingly, BRAFWT gets equally activated by upstream KRAS
mutations present in colon adenocarcinoma cells such as DLD-1 and SW620. Taken together, these results sug-
gest that the two oncogenes have different transforming capability in colon cancer, although they both use the
mitogen-activated protein (MAP) kinase pathway to carry out their effect. In general, BRAFV600E presents greater
potential in mediating tumorigenic effect as compared to KRASG12V both in vivo and in vitro. These findings may
have implications in personalised diagnosis and targeted therapeutics.
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Introduction
Colorectal cancer (CRC) can be either hereditary or sporadic charac-
terized by deregulated signal pathways and cellular programs through
gain and/or loss of function mutations that accumulate in a stepwise
manner. Among the most hurtful of all genetic abnormalities that
appear in CRC development are KRAS and its downstream effector
BRAF because they result to abnormal extracellular signal–related ki-
nase (ERK) signaling. Approximately 13% and 35% of CRC contain
activating point mutations in the BRAF and KRAS genes, respectively
[1–4]. Mutant RAS proteins end up losing their initially high GTPase
enzymatic activity [5], with mutations in codon 12 by far the most
frequent compared with codon 13 [1,6]. Recent evidence suggests that
different mutations in KRAS have different biological consequences
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in vivo. In addition, although G12D seems to be more frequent com-
pared with G12V in colon cancer, KRASG12V has been associated
with more aggressive colorectal carcinomas and greater mortality than
other codon 12 or 13 mutations [7–9]. Downstream the RAS-RAF–
mitogen-activated protein kinase (MAPK) pathway is BRAF, which is
activated through binding to RAS-GTP.
Activated RAF kinases phosphorylate MAPK/ERK kinase (MEK),
which in turn phosphorylate and activates ERK. BRAF has been
identified as an oncogene in human cancer especially in malignant
melanoma and colon carcinoma. Analysis of mutations in human co-
lorectal tumors showed that more than 80% of the BRAF mutations
were BRAFV600E (constitutive activation of BRAF kinase) and that this
mutation greatly increased ERK and nuclear factor κB signaling when
transformed in NIH3T3 cells [10]. It is believed that activated BRAF
and KRAS have a causal role in the development of cancer and cell
transformation [5,11,12]. Various RAS inhibitors have been examined
for their ability to block signaling in these constitutive active mutants,
and isoprenylation inhibitors have been proven to be ineffective in
clinical trials [13]. Therefore, greater focus has been placed on the
downstream RAF molecules.
BRAF and KRAS have the potential to regulate similar as well
as different pathways. Similarly, although phosphatidylinositol 3-kinase
(PI3K) is activated by Ras in fibroblasts, Ras is not an activator of the
PI3K/Akt pathway in T lymphocytes [14].
Mutational activation of oncogenes such as KRAS and BRAF
results to constitutive ERK signaling, which can lead to cell cycle
changes that have a profound influence on the G1/S transition by
regulating the expression of a number of cell cycle proteins such as
cyclins D and E and inhibitors such as p21Cip1 and p27kip [15,16].
Induction of senescence or tumorigenesis depends on the expres-
sion of cell cycle regulatory proteins (p21Cip1, p16INK4a, p14ARF,
p15INK4b, p19ARF, and p53). Similarly, cyclin D1 is equally impor-
tant for the development and progression of several cancers, in-
cluding colon cancer, and it has been found that it is significantly
upregulated and related to a more aggressive tumor phenotype and
poor prognosis [17,18]. Cyclin E, often found overexpressed in
cancer, can efficiently induce the phosphorylation of Rb, thus caus-
ing its functional inactivation, which contributes to tumorigenesis.
Similarly, high levels of the p21Cip1 inhibitor have been associated
with RAS signaling and with the clinical progression of malignant
melanoma [19]. All these incidents have in common a mutated
BRAF or KRAS gene and result to high cell proliferation through in-
creased ERK signaling. Nevertheless, hyperactivation of the ERK
pathway can also lead to the opposite situation, cell cycle arrest,
and p53-dependent or -independent senescence [20–22]. More spe-
cifically, sustained BRAFV600E expression in human melanocytes in-
duces cell cycle arrest, along with induction of both p16INK4a and
senescence-associated β-galactosidase (SA-β-Gal) activity [23]. By
contrast, the expression of oncogenic RAS in primary human or ro-
dent cells results in premature senescence and allows proliferation to
continue unabated in the presence of oncogenic stimuli [24].
Oncogenes have differential effects in colon cancer progression
[25]. Because BRAF and KRAS are oncogenes in the same pathway
and yet are mutually exclusive in colon cancer [26], further analysis
to dissect their function of transformation in the colonic epithelium
may reveal marked functional differences about their oncogenic po-
tential and tissue-specific pathway activation. Caco-2 cells are derived
from a typical colon adenocarcinoma and are often used in the study
of enterocyte differentiation because on reaching confluence, the cells
differentiate into a mature enterocyte phenotype, characterized by
the formation of microvilli and brush borders [27]. Caco-2 cells har-
bor a truncating mutation in the APC gene [28], a Smad4 C-terminal
missense mutations [29], and are further mutated at the p53 locus,
generating a stop codon at amino acid 204, resulting in no detectable
p53 expression [30]. Thus, these cells represent an ideal model sys-
tem in which to study the transforming effects of BRAF and KRAS
activating mutations in a transformation-permissive genetic back-
ground. Overexpression of these oncogenes in Caco-2 will also allow
to study how the genetic background of a cell affects the outcome
of an activating mutation and all that in comparison with commer-
cially available human colon cancer cell lines carrying a more com-
promised mutated background, such as HT29V600E, Colo205V600E,
DLD-1G13D, and SW620G12V. Briefly, we established stable Caco-2
cell lines constitutively expressing BRAFV600E (Caco-BR13, -BR23)
or KRASG12V (Caco-K6, -K15) and a control cell line stably trans-
fected with the empty expression cassette (Caco-Neo). Clone selection
was based on the protein expression levels for the two oncogenes, and
their characterization was performed both in vivo and in vitro.
Materials and Methods
Stable Transfection and Characterization of Caco-2 Cells with
BRAFV600E and KRASG12V
The plasmids pH8-BRAFV600E, kindly provided byDr. Tsuneo Ikenoue
(Department of Gastroenterology, Tokyo, Japan), and pcDNA3-
KRASG12V [31] were transfected into Caco-2 cells using calcium phos-
phate. As a control, Caco-2 cells were also transfected with an empty
pcDNA3 expression vector, and the arising clones were established by
clonal selection with 0.5mg/ml geneticin (Sigma-Aldrich, Poole, UK).
Successful clones were further selected on the basis of protein expres-
sion for each oncogene. New BRAFV600E and KRASG12V clones were
named Caco-BR (or briefly BR) and Caco-K (or briefly K), respectively.
The growth rate of newly established clones was determined in
replicate wells of a six-well dish seeded at 1 × 105 cells per well. Cells
were harvested by trypsinization and counted using a Coulter counter
(Model Z2; Coulter, Miami, FL) on days 1 to 5. For the anchorage-
independent growth on soft agar, a layer of 0.5% agar in growth
medium was first set in each well of a six-well dish. Growth me-
dium containing 0.3% agar was mixed with 1 × 103 cells per well
and overlaid onto the first layer of agar. Cells were allowed to form
colonies in 5% CO2 for 2 weeks at 37°C, fixed with methanol for
10 minutes at room temperature, and stained with 0.01% crystal
violet. The colony formation was examined with a ×30 objective of
an inverted light microscope (Axiovert 25; Zeiss, Jena, Germany),
and the total number of colonies in the top layer of agar was de-
termined. To investigate the tumorigenicity of the clones, approxi-
mately 1 × 106 cells (Caco-2, Caco-NEO9, Caco-BR13, Caco-BR23,
Caco-K6, Caco-K15, HT29, and DLD-1) in a total volume of 100 μl
of PBS were subcutaneously injected into each flank of a severe
combined immunodeficient (SCID) mouse (Charles River Laborato-
ries, Inc., L’Arbresle, Cedex, France) and monitored for tumor forma-
tion for a period of 5 months. All animal experiments were approved
by the Animal Ethics Committee of the Institute of Biological Re-
search and Biotechnology, National Hellenic Research Foundation,
and procedures were according to the guidelines approved by theUnited
Kingdom Coordinating Committee of Cancer Research [32]. Tumors
were isolated from each condition after 2 weeks of their appearance,
and their weight was determined.
Neoplasia Vol. 11, No. 11, 2009 Differential BRAFV600E to KRASG12V Colon Adenoma Cancer Oikonomou et al. 1117
Protein Immunoblot Analysis
Whole cell lysates were prepared with lysis buffer containing pro-
tease and phosphatase inhibitors and were subjected to Western blot
analysis. Methodology and antibody information is listed in Supple-
mentary Materials and Methods.
Adherent Cell Proliferation Assay
Cells were plated into a 96-well plate at a density of 2 × 103 per
well and left to grow for 24 hours. Cells were treated with two
different concentrations of UO126 (30 and 60 μM; ALX-270-237-
M001; Alexis Biochemicals, Lausen, Switzerland) in triplicates. In each
instance, cells were left to grow for 72 hours before being treated with
100 μl of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide (MTT) (M2003; Sigma, St. Louis, MO) for 4 hours. MTT crys-
tals were solubilized using isopropanol. The resulting absorbance was
read in a Tecan Safire2 Microplate Reader (Tecan Austria GmbH,
Grodig, Austria) at 560 nm. Absorbance readings were subtracted from
the value of blank wells; the reduction in cell growth was calculated as
a percentage of control absorbance in the absence of any inhibitor.
Senescence-Associated β-Galactosidase
Cells were washed twice with PBS, fixed with 2% formaldehyde
and 0.2% glutaraldehyde prepared in PBS for 5 minutes, and washed
twice with PBS. Cells were stained with X-Gal solution pH 6 (1 mg/ml
X-Gal, 5 mMK3Fe[CN]6, 5 mMK4Fe[CN]6, 2 mMMgCl2, 150 mM
NaCl, 40 mM citric acid prepared in sodium phosphate buffer) pre-
pared in PBS. Staining was performed at 37°C for approximately
16 hours without CO2 [33]. Images were obtained using a Nikon
Eclipse T-200 (Tokyo, Japan) inverted phase-contrast microscope
equipped with an Olympus digital camera (Olympus, SP-51OU2,
Hamburg, Germany). The objective lens used was ×30.
Immunofluorescence in Cultured Cells
Cells were grown on cover slips and fixed using 2% paraformal-
dehyde in PBS for 10 minutes at room temperature. Permeabilized
cells were blocked with 4% FBS at room temperature for 1 hour
and stained with anti-PML antibody (clone PGM3, SC-966; Santa
Cruz Biotechnology, Santa Cruz, CA) overnight at 4°C. Secondary
antibody Alexa Fluor 488 goat anti-mouse (1:600, A11001; Molecular
Probes, Eugene, OR) was applied to the cells for 1 hour at room tem-
perature. The nuclei were stained with Hoechst No. 33342 (B2261;
Sigma) for 10 minutes and coverslips were mounted on glass slides in
Gelvatol/DABCO aqueous medium (Sigma-Aldrich). Samples were
visualized with a Leica TCS SPE confocal laser scanning microscope,
and image acquisition was via the LAS AF software, both from Leica
Lasertechnik, Heidelberg, Germany. The objective lens used was ×63.
Flow Cytometric Analysis of Cell Cycle
For flow cytometry, 5 × 106 cells washed with PBS and fixed over-
night with ice-cold 70% ethanol at −20°C. After fixation, cells were
stained with 1 mg/ml propidium iodide in PBS solution containing
20 μg/ml RNaseA and incubated at 37°C for 20 minutes. Samples
were analyzed by flow cytometry (Calibur, Becton Dickinson, UK).
To further study cell cycle checkpoints, cells were treated with growth
medium containing 0.1 μM nocodazole (M1404; Sigma), which is
known to block cell cycle progression in G2-M through disruption of
mitotic spindles, for 2, 8 and 16 hours.
Gene Expression Reverse Transcription–Polymerase Chain
Reaction Analysis
Total RNA (3 μg) was reverse-transcribed into complementary
DNA using the SuperScript II Reverse Transcriptase (Invitrogen,
Karlsruhe, Germany) according to the manufacturer. Additional de-
tails are provided in Supplementary Materials and Methods.
Microsatellite Instability Analysis
Both Caco-BR cell lines, the parental cell line Caco-2 and micro-
satellite instability (MSI)–positive colon cancer cell lines DLD-1 and
HCT116 were used to independently study MSI status by allelic pro-
filing of mononucleotide repeat sequences (NR-21, NR-22, NR-24,
BAT-25, and BAT-26) within the 3′ and 5′ untranslated regions of
five different genes as previously described [34]. Briefly, one primer
in each pair was labeled with one of the fluorescent markers 6-
carboxyfluorescein (FAM), 6-carboxytetramethylrhodamine (TAMRA),
or dichloro-2′,7′-dimethoxy-6-carboxyfluorescein ( JOE). Each mono-
nucleotide repeat was amplified individually. Polymerase chain reac-
tion (PCR) products were purified with Gene Clean Turbo PCR Kit
(Bio101; QBiogene, Illkirch, Strasbourg, France) according to the man-
ufacturer’s instructions and were subsequently quantified on a 2% gel
against molecular weight markers. Purified PCR products were directly
gel-sequenced using an ABI PRISM 3100 genetic analyzer (MWG-
Biotech; Ebersberg, Germany).
Results
Characterization of Caco-2 Clones Expressing Mutant
BRAFV600E (Caco-BR) and KRASG12V Oncogenes (Caco-K)
Plasmid (pH8-BRAFV600E and pcDNA3-KRASG12V) concentra-
tions were selected to provide an efficient protein expression of
Figure 1. BRAFV600E significantly alters morphology and growth characteristics of Caco-2 cells. (A) Western blot analysis from selected
Caco-2 clones stably transfected with KRASG12V (Caco-K6 and Caco-K15) and BRAFV600E (Caco-BR13 and Caco-BR23) oncogenes. Left
panel shows the expression levels of total KRAS and phosphorylation status of ERK1/2. Right panel shows the expression levels of total
BRAF, active pBRAF, and phosphorylation status of ERK1/2. The vertical dividing black line indicates multiple fields taken from the same
image. (B) Growth rate of Caco-2, Caco-NEO9, Caco-BR13, Caco-BR23, Caco-K6, and Caco-K15 cells. Results presented are average
expression levels from at least three independent experiments. (C) Photographs illustrate the altered spindle-like morphology induced by
BRAFV600E. Representative images. Original magnification, ×30. (D) BRAFV600E efficiently transforms Caco-2 cells both in vivo and
in vitro. Tumor formation efficiency of different Caco-BR and Caco-K cells and control colon cancer cells was assessed in SCID mice
during a period of 5 months after cell injection. Tumor number represents successful tumor formed per group of cell line used. Tumor
size (cm) and weight (g) describe the isolated tumors 2 weeks after their appearance per group of cell line used. For the SCID mice
experiment, two or three 5-week-old female athymic mice were used per cell line. The values are mean ± SD of three individual experi-
ments performed in duplicates and triplicates. Accordingly, their ability to form colonies on 0.3% soft agar for 2 weeks was assessed
and is represented in the table under the colony number. For soft agar assays, data were accumulated from two independent experi-
ments, each clone in triplicate. ND indicates not determined; NI, not included in the experiment.
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BRAFV600E and KRASG12V. Initially, 10 different clones were se-
lected for each oncogene and empty vector and checked for presence
of the plasmid (data not shown). Although we isolated clones ex-
pressing varying amounts of mutant protein (data not shown), we
avoided further analysis of clones that expressed very high or very
low levels (lower compared to controls) of transgene. For further
analysis Caco-K6 and -K15 [31], clones were selected in case of
KRASG12V transformation, whereas Caco-BR13 and -BR23 were
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the selected clones that expressed relatively low levels of highly phos-
phorylated BRAFV600E (Figure 1A). In both cases of transformation,
the level of oncoprotein was of similar expression compared with the
control. To examine how the two mutations related to the down-
stream activities of signaling components known to be regulated
by the RAS-RAF-MAPK pathway, we examined the phosphorylation
status of ERK1/2 where both oncogenes managed to induce signifi-
cant activation of this kinase (Figure 1A).
BRAFV600E Alters Cell Growth and Cellular Morphology
and Mediates Cell Transformation More Efficiently
than KRASG12V
We noted that Caco-BR13 and -BR23 cell lines grew with differ-
ent kinetics to Caco-K6 and -K15 and control cell lines (Caco-2 and
NEO9) exhibiting a high proliferation rate and significantly quicker
doubling times (Figure 1B). Caco-2 and NEO9 cell lines grew with
similar kinetics. Photographs of Caco-2, NEO9, Caco-BR, and
Caco-K cells illustrate the altered morphology specifically induced
by the BRAFV600E transformation (Figure 1C ). Caco-BR cells seem
to have adopted a spindle-shaped morphology and stopped forming
large islets compared with Caco-2. However, even the Caco-2 clones
expressing the highest levels of KRASG12V did not adopt this altered
morphology, as previously shown [31]. In comparison, Caco-K cells
formed tight contacts evidenced by their preference to grow in col-
onies with distinct boundaries between each cell (Figure 1C ). In
summary, our results demonstrate that the establishment of an al-
tered more transformed morphology was restricted to expression of
the mutant BRAF.
The tumor-inducing potential of each oncogene in vivo was exam-
ined in SCID mice, in which Caco-BR13 and -BR23 allowed the
formation of significantly larger tumors than Caco-K6 and -K15
in significantly less time, whereas tumor formation of Caco-K cells
varied from 1 to 5 months in some animals (Figure 1D). Moreover,
both oncogenes (BRAFV600E and KRASG12V) significantly increased
the ability of Caco-2 cells to grow in soft agar (Figure 1D). Similarly,
Caco-BR cells consistently formed colonies more efficiently than
Caco-K cells and generated the same number of colonies on average
with HT-29 cancer cell line (Figure 1D). BRAFV600E confers higher
transforming activity to Caco-2 cells compared with KRASG12V both
in vivo and in vitro.
BRAFV600E and KRASG12V Downstream Signaling
Analysis of the RAS-RAF-MEK-ERK pathway showed more
efficient downstream ERK phosphorylation in the presence of
KRASG12V rather than BRAFV600E. Nevertheless significant was the
activation of ERK2 (lower pERK1/2 band) in Caco-BR cells. In con-
trast, upstream ERK1/2 activator MEK was more activated in the
Caco-BR cells, suggesting that other factors may be implicated in
BRAFV600E signaling, considering that the family member Raf-1
(CRAF) was found to be equally expressed and activated as BRAF
in Caco-BR cells (Figure 2, A and B). To elucidate differential ERK
activity, molecules that regulate its activation were analyzed. It was
found that in Caco-BR cells (and not in Caco-K cells), kinase suppres-
sor of RAS (KSR), a positive regulator of ERK activation, was signif-
icantly downregulated (Figure 2B). However, no significant change
was observed in the RAF-1 kinase inhibitory protein (RKIP) gene sug-
gesting no involvement (Figure W1). Therefore, limited KSR availabil-
ity in the BRAFV600E system may be responsible for the moderate
ERK activation regardless of increased BRAF-MEK activity.
Analysis of other RAS effector pathways showed that the survival
pathway PI3K (pAKT) was significantly activated in the Caco-K
cells, whereas the Jun N-terminal kinase ( JNK) pathway was found
to be downregulated in the Caco-BR cells (Figure 2C ). Finally, the
Ral pathway (RalA-GTP) remained unaffected in either case of on-
cogenic transformation (Figure W2).
Comparison of the RAS-RAF-MAPK signaling pathway in HT29
and Colo205 cells (V600E) versus DLD-1 and SW620 cells (G13D
and G12V, respectively) revealed that, although pBRAF was higher
in KRAS mutant cells, the pathway was more active in the BRAF
mutant cell lines (Figure 2D).
Pharmacologic Inhibition of MAPK Signaling Pathway
To further explore ERK signaling, we analyzed its localization by
immunostaining and discovered that, in Caco-BR cells, pERK was
mainly localized in the nucleus compared with Caco-K and control
cells, where it was found in the cytoplasm (Figure 3A). Pharmacolog-
ical inhibition of the biochemical activities caused by mutant BRAF
and KRAS was achieved using the specific MEK inhibitor UO126
in the presence of which cell growth of both Caco-BR and Caco-K
cells was significantly reduced by approximately 50% to 60%, re-
spectively, as shown by the MTT assay (Figure 3B). Under adher-
ent culture conditions, the MEK inhibitor UO126 blocked growth
through down-regulation of pERK within 1 hour and determined
that cyclin D1 is the transcriptional target of KRASG12V. However,
UO126 seemed insufficient in blocking cyclin D1 in Caco-BR cells
in which pERK seemed to have a dynamic response to the treatment
and recovers rapidly (Figure 3C ).
Differential Expression of Senescence Markers by
Oncogenic KRASG12V
Overexpression of KRASG12V but not BRAFV600E in Caco-2 cells
led to the acquisition of premature senescence-related markers as de-
termined by SA-β-Gal staining (Figure 4A) and increased promyelo-
cytic leukemia (PML) gene product localization, which has been
previously associated with cellular senescence in RAS-arrested cells,
and can provide further evidence of senescence activity [35] (Fig-
ure 4B). Regardless of senescence appearance, the cells did not ar-
rest but continued proliferating and even increased their growth
rate compared with Caco-2 cells (Figure 1B). Pigmentation that ap-
pears in the Caco-2 and NEO9 control cells after SA-β-Gal staining
is considered as background staining because it is not comparable to
the positive control staining (human embryonic lung fibroblasts
HFL1 at PD55; Figure 4A). To determine whether oncogene-induced
senescence in Caco-2 cells is mediated by the MAPK signaling path-
way, pharmacological inhibition of ERK1/2 using UO126 was per-
formed. Blocking of the MAPK pathway for 48 hours in Caco-K
cells resulted in regression of the senescence-activated β-gal activity
(Figure 4C).
In a parallel experiment, cell growth on growth factor depletion was
analyzed for 3 to 5 days after which significant cell death was observed
microscopically in Caco-K cells when Caco-BR cells and control cells
continued proliferating normally (Figure 4D). This is of interest, con-
sidering that Caco-2 cells after KRASG12V transformation acquired
senescence markers and at the same time growth factor–dependent
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Figure 2. The MAPK pathway is activated in the Caco-BR and Caco-K cells. (A) Expression analysis of KRAS/RAF and biochemical de-
tection of activated RAF proteins. (B) Signaling downstream of KRASG12V and BRAFV600E and mRNA levels of KSR-positive regulator of
pERK. (C) RAS effector pathways (PI3K and JNK) differentially regulated by KRASG12V and BRAFV600E, respectively. (D) Biochemical de-
tection of activated BRAF and its downstream effector ERK in control cell lines. Results presented are average expression levels among
three independent experiments. Verticals dividing black lines indicate multiple fields taken from the same image.
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viability. Hoechst staining of Caco-K cells grown in the absence of
serum was used to show death by apoptosis (Figure 4E).
These experiments show a clear difference in cell senescence marker
staining between Caco-K and Caco-BR cells, which probably dra-
matically affects differential viability of these cells under growth fac-
tor deprivation.
Rb Inactivation and p19 ARF Collaborate with BRAFV600E in
Oncogenic Transformation
D-type cyclins (D1 and D3; G1-phase cyclins), which prepare
chromosomes for replication and initiate Rb phosphorylation, were
significantly overexpressed in the Caco-BR transformed cells (Fig-
ure 5A). Nevertheless, both cyclins A and E (S-phase cyclins) were
also significantly overexpressed in Caco-BR cells. These proteins ini-
tiate S phase as soon as M phase is over, supporting DNA replica-
tion along with E2Fs, and inactivate the Rb protein by completing
its phosphorylation. These results come to support the finding that
the Rb is hyperphosphorylated and therefore inactivated in Caco-BR
and not in Caco-K cells (Figure 5B). Nonphosphorylated Rb protein
in the Caco-K cells is consistent with the appearance of senescent
characteristics in those cells as described earlier (Figure 5, A and B).
Activation of the RAS-RAF pathway is known to mediate some of
its effects through the activation of p16Ink4A and p19ARF [36]. Be-
cause p16Ink4A is hypermethylated in Caco-2 cells [37], analysis was
performed for the alternative reading frame of the same locus, the
p19ARF transcript along with other cell cycle regulators at transcrip-
tional level (Figure 5C ). Two members of the Ink family (p19ARF and
p15Ink4C) were upregulated only in Caco-K cells, whereas the
p27Kip1 member of the Cip/Kip family was upregulated in both cases
of oncogenic transformation. Interestingly, p21Cip1 and p19Ink4D
were upregulated in Caco-BR cells. The cell cycle inhibitor p57Kip2
was the only gene not altered between the two oncogenes but up-
regulated compared with Caco-2 parental cell line (Figure 5C). Con-
trol cell lines HT29 (bearing endogenous BRAFV600E) and DLD-1
(bearing endogenous KRASG13D) were also analyzed. The analysis re-
garding cell cycle inhibitors was limited to reverse transcription–PCR
Figure 3. ERK localization and the pharmacological inhibition of MAPK pathway. (A) Nuclear localization of pERK in Caco-BR cells. Rep-
resentative confocal immunofluorescence images, double labeled with Hoechst (blue) and pERK (green). Original magnification, ×63.
(B) Pharmacological inhibition of cell proliferation using the MEK inhibitor UO126 at 30 and 60 μM for 72 hours and analyzed by MTT
assay in Caco-BR and Caco-K cells. The inhibitor was replaced every 24 hours, and data in triplicates were normalized to the negative
controls. (C) Determination of the inhibitory effect of 60 μM UO126 on pERK and cyclin D1 for various time points at the protein levels.
Results were consistent among three independent experiments.
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Figure 4. Induction of KRASG12V induces senescence-related markers in Caco-2 colon epithelial cells as determined by (A) SA-β-Gal
(representative images; original magnification, ×30) and (B) PML bodies staining (representative confocal immunofluorescence images,
double labeled with Hoechst (blue) and PML (green); original magnification, ×63). (C) Pharmacologic inhibition of ERK1/2 using 30 μM
UO126 for 48 hours resulted in regression of the senescence-activated β-gal activity in Caco-K cells. The inhibitor was replaced every
24 hours. Representative images. Original magnification, ×30. (D) Cell growth on growth factor depletion. Significant cell death was
observed microscopically in Caco-K cells after 5 days of serum starvation, whereas Caco-BR and control cells (Caco-2, HT29, DLD-1)
continued proliferating normally. All cells were cultured in triplicates with 0% and 10% FBS in parallel for comparison, and medium was
replaced every day. (E) Hoechst staining showed apoptotic characteristics in the Caco-K cells after serum starvation. Representative
images. Original magnification, ×30.
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(RT-PCR) because of the poor quality results yielded by the avail-
able antibodies.
BRAFV600E Induces MSI in Caco-2 Cells by Altering DNA
Content and Cell Cycle Distribution
The ability of transfected oncogenes to modulate the cell cycle dis-
tribution of Caco-2 cells was measured by FACS analysis. BRAFV600E
oncogene caused major cell cycle alterations when compared with pa-
rental Caco-2 cells, whereas no alterations were incurred in the pres-
ence of activated KRAS. Of interest is the fact that, after BRAFV600E
transformation, a new population of cells was generated that seems to
contain a hypodiploid number of chromosomes and therefore a lower
amount of DNA content. This is depicted by a shift to the left, on
the FL2 axis, of the corresponding G1 phase in both Caco-BR clones
(hypodiploid peak; Figure 6A). To exclude the possibility of this be-
ing an apoptotic cell population, cells were treated with nocodazole
for various time points after which there was a time-dependent
Figure 4. (continued).
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Figure 5. Differentially expressed cell cycle regulators in Caco-BR and Caco-K cells. (A) Protein analysis of cyclins A, B1, D1, D3, and E1
as well as (B) phosphorylation status of the Rb protein in KRASG12V versus BRAFV600E clones and control cancer cells (HT29 and DLD-1).
(C) Transcription analysis by RT-PCR of cell cycle inhibitors. Results were consistent among three independent experiments. Horizontal
dividing black lines indicate group of images acquired with exact same conditions on a separate experiment. Vertical dividing black lines
indicate multiple fields taken from the same image.
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Figure 6. BRAFV600E induce MSI in Caco-2–transformed cells. (A) FACS analysis of cell populations after propidium iodide staining re-
veals altered cell cycle distribution in BR- cells. M1 indicates sub-G1 phase; M2, G1 phase; M3, S phase; M4, G2/M phase. (B) Cells
challenged with 0.1 μM nocodazole to establish a time dependent reduction in the hypodiploid peak with a gradual shift of the cell
populations toward the right on the FL2 axis. Cell cycle progression toward the G2/M phase was monitored at the indicated time points
and progressive appearance of dead cells at 8 and 16 hours and excluded the presence of apoptosis, which only appears after the
16-hour treatment point. Results were consistent among three independent experiments. (C) Relative RNA levels of DNA repair genes
in Caco-BR and Caco-K cells and control HT29 and DLD-1 human colon cancer cell lines were evaluated by RT-PCR analysis. The analysis
was performed in triplicates and the mean ± SD is shown. DNA repair genes downregulated as a result of BRAFV600E-induced transfor-
mation in Caco-2 cells. Columns indicate relative RNA level normalized to glyceraldehyde 3-phosphate dehydrogenase. (D) Electrophero-
gram of the mononucleotide repeat markers NR-21, NR-22, NR-24, BAT-25, and BAT-26 of BRAFV600E-transformed cells, their parental cell
line Caco-2, and MSI-positive cell lines DLD-1 and HCT116. The appearance of numerous mononucleotide repeats of lower molecular
weight in BR- cells in more than two MSI markers indicates MSI-H. Dashed line indicates the reference point relative to Caco-2 cells.
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reduction in the hypodiploid peak with a gradual shift of the cell
populations toward the right on the FL2 axis (Figure 6B). Cell popu-
lation movement of the hypodiploid peak suggests ongoing cell cycle
and is confirmed by statistical analysis of the percent of gated cells at
each time point (data not shown). It is worth mentioning that during
the 2-hour treatment with nocodazole, Caco-BR dividing cells colo-
calized with the G1-phase peak of Caco-2–untreated cells. This obser-
vation could further support the lower DNA content in these cells.
Therefore, the novel finding presented here suggests that BRAFV600E
oncogene may induce MSI characteristics to Caco-2 cells (Figure 6A).
Regarding the hypothesis of BRAFV600E-induced MSI, specific
DNA repair (MSH2 and Ku70) as well as nucleotide excision repair
(NER) genes (ERCC1-variant 1, ERCC3, and XPC ), found to be
significantly downregulated in a microarray analysis (Joyce et al., un-
published observations) in Caco-BR cells, were validated by RT-PCR
analysis to further support this hypothesis (Figure 6C ).
The distinct role of BRAFV600E with respect to mediating MSI
was further supported by the allelic profiling of NR-21, NR-22,
and NR-24 in which Caco-BR cells presented lower molecular
weight fragments, visible as peaks that had shifted to left and varied
in 4 bp or greater (Table W2) compared with the parental cell line
Caco-2. When comparing Caco-BR cells to MSI-positive cell lines
DLD-1 and HCT116 [6,38]; the eletrophoretic pattern was only
comparable with that observed in NR-22. In case of NR-21 and
NR-42 loci, DLD-1 cells were represented by two distinct cell pop-
ulations, one has been represented by normal-sized alleles and the
other by peaks shifted to left, whereas the HCT116 were only repre-
sented by the lower molecular weight fragments. Both situations refer
to MSI (Figure 6D). In contrast, the shift observed in BAT-25 and
BAT-26 loci was bellow the cutoff level (≥4 bp) for Caco-BR23 but
not Caco-BR13 and was considered to represent a polymorphism
or somatic alteration. As previously, HCT116 were once again
represented by a new cell population of lower molecular weight
in BAT-26 locus, whereas a shift to the left (≥4 bp) was observed
in BAT-25. Similarly, DLD-1 cells showed evidence of MSI in both
BAT-25 and BAT-26 loci that were represented by shifts to the left
(≥4 bp; Figure 6D).
Discussion
Differential Human Colon Cell Transformation by Oncogenic
BRAF and KRAS
Several studies have investigated the role of BRAFV600E and
KRASG12V acting as oncogenes, but no study so far has compared
these two activating mutations for their relevant transforming capa-
bilities in colon cancer cells. Although it has been reported that
BRAFV600E is oncogenic when transfected into melanocytes [12],
others have shown that BRAFV600E transforms NIH3T3 immortal
fibroblasts less efficiently than HRASG12V [11] and that its expression
confers rat thyroid cells with little growth advantage because of con-
comitant activation of DNA synthesis and apoptosis [39]. Results
obtained in the present study point toward the presence of a potent
machinery carrying out aggressive transformation in the Caco-2 cells
transfected with the BRAFV600E oncogene.
BRAFV600E and KRASG12V Signal Through ERK1/2 to
Transform Caco-2 Colon Cells
Although KRASG12V could activate ERK more efficiently, it was
BRAFV600E that mediated complete transformation of colon epithe-
lial cells. However, although MEK activation in Caco-BR cells was
more potent, it did not lead to significantly increased ERK signaling
as previously described for BRAFV600E [40]. In a similar study where
BRAFV600E was compared to HRASG12V, pERK levels were compara-
ble to basal in the case of BRAFV600E [41]. Furthermore, it was ob-
served that, in Caco-BR cells, there was a marked difference between
the two ERK isoforms, namely, ERK1 and ERK2, with the latter be-
ing far more activated. The important role of ERK2 in tumor growth
has been recently revealed through RNAi-mediated knockdown,
where ERK2 but not ERK1 inhibited growth of liver cancer cells
in vitro and in vivo and silencing of ERK2 in NIH3T3 cells slowed
down cell proliferation [42,43]. Taking into account that Caco-BR
cells have enhanced cell growth, this selective ERK2 activation
may play a crucial role in the regulation of cell proliferation in the
BRAFV600E-transformed cells regardless of moderate ERK activity. In
addition, localization of pERK in the nucleus explains why moderate
ERK activity is sufficient for the cell transformation of Caco-BR cells
because activated ERK is translocated to the nucleus where it can
phosphorylate and activate several molecules, such as cyclin D1, which
is significantly activated and hyperphosphorylated in these cells. In-
creased kinase activation was also recorded for CRAF, coexpression
of which can induce a B/C RAF complex in a RAS-dependent manner,
inducing distinct biochemical properties [44]. A different explanation
for the moderate but efficient ERK activation may lay with the fact
that excessive amount of ERK signaling can lead to cell cycle arrest
or senescence, and cells have been shown to switch from BRAF to
CRAF signaling to avoid this [45]. Pharmacologic inhibition of the
MAPK signaling pathway with respect to the hyperproliferative phe-
notype of Caco BR cells, and to a lesser extent, of Caco K cells was
indicative that MAPK pathway is mediating cell transformation. ERK
inhibition was more potent in case of KRASG12V cell transformation
and had a profound effect on the transcriptional target cyclin D1.
Other RAS effector pathways such as the JNK and the PI3K were
found differentially regulated between the two oncogenes, and no
modulation was detected for Ral. These observations indicate that
the expression of these oncoproteins induces abundant as well as var-
iable downstream signaling in the colonic epithelium.
Also of interest is the significant activation of BRAF kinase in both
DLD-1 and SW620 colon cancer cells, as a result of the upstream
KRAS mutation present in these colon adenocarcinomas [46], which,
however, does not induce pERK. However, the presence of BRAFV600E
in HT29 and Colo205 cells induces low pBRAF and high pERK. It is
worth noting that the genetic background of these cell lines, apart
from a KRAS or BRAF mutation, includes several other (p53, APC,
PI3K, SMAD4). Here, we show the differential properties of two
frequently mutated oncogenes in a permissive genetic background
(in Caco-2 cell line) and how much these properties vary in the
context of other mutations (e.g., HT29 and DLD-1 cell lines). This
finding may have in vivo implications for personalized therapeutics in
the future, considering how these mutations may influence pathway
cross talk.
Attenuation of ERK Activation Due to KSR
Down-regulation by BRAFV600E
Nevertheless, the RAS-RAF-MAPK signaling pathway is not a
simple one because many molecules have been identified to regulate
its function. For example, signal flow from RAF to MEK is believed
to be regulated by scaffold proteins such as KSR and protein inter-
action disrupters such as RKIP [47]. KSR is a putative scaffolding
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protein for the RAF-MEK-ERK module that positively regulates
ERK activation by binding to MEK and ERK constitutively [48].
In the present study, KSR was found significantly downregulated
in the Caco-BR cells, and this could account for the moderate levels
of ERK activation detected. Studies that associate KSR with cancer
progression led to assume that pharmacological inactivation of KSR
may serve as a treatment for RAS-driven malignancies, such as pan-
creatic cancer [49].
Presence of Rb and p19 ARF Overexpression Is Not Sufficient for
RASG12V-Induced Transformation
We report here that colon epithelial cells transformed by BRAFV600E
presented no sign of senescence, whereas premature senescence was
detected in the Caco-K cells, which also had ongoing cell cycle. To
identify the exact mechanism by which KRASG12V switches from pro-
moting proliferation to inducing senescence mechanism, the MAPK
pathway was pharmacologically blocked, and replicative senescence
was successfully prevented. Therefore, hyperactivation of the ERK
pathway in Caco-K cells seems to lead to the opposite situation, which
are the induction of a senescence program, growth factor–dependent
cell viability, and finally not efficient cell transformation, which are not
observed in Caco-BR cells.
Because in the parental Caco-2 cells the p53 is mutated and the
p16Ink4 tumor suppressor is hypermethylated, the remaining possible
mediator of senescence in the KRASG12V is the Rb pathway. Studies
have shown that overexpression of RASG12V or Raf1 by retroviral de-
livery in normal human fibroblasts disrupted the Rb pathway [21,50].
In the present study, although the Rb was found to be selectively
hyperphosphorylated and therefore deactivated in the Caco-BR cells,
it was still functional in the Caco-K cells in which the p19ARF was also
significantly overexpressed. Together, these data show that both the Rb
and the p19ARF are working to induce senescence-related markers in
Caco-K cells, which, however, escape from growth arrest. Cell survival
could also be facilitated by the selective activation of AKT observed
in the Caco-K cells. RAS-induced senescence has not been fully eluci-
dated and is considered to be the coordinated output of cell type–
specific signaling networks [51]. This is further supported by the fact
that additional growth factor extrinsically regulated signaling pathways
are important for the viability of Caco-2 cells, whereas Caco-BR cell
viability is not dependent on extrinsic growth factors. Increased pro-
liferation of Caco-BR cells could be well explained by the increased
expression of most cyclins including cyclin D1, D3, A, and E. Sig-
nificantly increased expression of D cyclins could also account for
the increased p21Cip1 because it has been shown that cyclin D1 spe-
cifically inhibits its degradation [19]. Both oncogenes (BRAFV600E and
KRASG12V) increase cyclin D1, which, when combined with Cdk4
and Cdk6, phosphorylates and inactivates Rb; however, this is not
the case for the Caco-K cells. Accumulated p27Kip1 manages to take
advantage of the hypophosphorylated Rb in the Caco-K cells and
silences cyclin D/Cdk2 complex that may be present in the early G1
phase. Working along this hypothesis, KRASG12V signaling is efficient
in inducing cyclin B1, the most powerful mediator of cell cycle. Cyclin
B1 is the cyclin localized in the cytoplasm, and its activation may be a
direct signaling from increased cytoplasmic ERK in Caco-K cells.
BRAFV600E-Mediated MSI in Caco-2 Cells
Cell cycle distribution of Caco-2 cells was notably affected after
BRAFV600E transformation because it was represented by a general
shift to the left of the FL2 axis. This was indicative of a cell popu-
lation with a lower DNA content due to a hypodiploid number of
chromosomes. Nocodazole treatment of cells revealed that these cells
were normally proliferating because they progressed through the M
and G2 phases. However, their dividing capacity was diminished,
characteristic of cells containing a hypodiploid number of chromo-
somes. In a recent study, BRAFV600E overexpression in a rat thyroid
cell (PCCL3) among others managed to induce chromosomal in-
stability (CIN) [39]. Caco-2 cells that are characterized by CIN ac-
quire MSI characteristics in the presence of BRAFV600E, a hypothesis
also supported by a microarray analysis in the Caco-BR cells ( Joyce
et al., unpublished observations). The microarray study revealed
Figure 7. Differential effects of KRASG12V and BRAFV600E on cell cycle. BRAFV600E drives cells to high proliferation rate through nuclear
pERK and the consequent phosphorylation of cyclin D1 (A), whereas KRASG12V generates senescence-related characteristics mediated
by high cytoplasmic levels of pERK (B).
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down-regulation of essential DNA repair (MSH2 and Ku70) and
NER genes (ERCC1-variant 1, ERCC3, and XPC ). Validation of ar-
ray results confirmed down-regulation of ERCC1, ERCC3, and XPC
in Caco-BR cells, all members of the NER subfamily. Deregulation
in one of these NER members may result to failure of DNA repair
initiation and cause defects in the mismatch repair mechanisms and
its gene members [52]. Notably, DLD-1, already described to have
MSI, also presents a significant down-regulation of ERCC1-variant 1
gene, and their FACS profile is comparable to that of Caco-BR cells’.
BRAF mutations have long been connected with MSI sporadic colo-
rectal tumors because mismatch repair–deficient tumors have a very
high incidence of BRAF mutations, and its overexpression in a rat cell
line of thyroid origin (PCCL3) induced CIN [39,53–55]. The role
of BRAFV600E in MSI is further elucidated through the allelic profil-
ing of certain mononucleotide repeats widely used to determine the
microsatellite status. In particular, more than two of five analyzed loci
(NR-21, NR-22, NR-24, BAT-25, and BAT-26) show instability in
the Caco-BR cells, and therefore, we classify them as MSI-high
(MSI-H) [56]. Because MSI cell lines display higher sensitivity to
chemotherapeutics (CPT-11) than MSS cells, this could be later
exploited to tailor chemotherapy based on MSI status [57,58].
We propose that the effect of BRAFV600E, elicited on mitotic im-
pairment, triggers chromosome breakage in the presence of a defec-
tive DNA damage response mechanism. As a result, cells continue
cycling and acquire, within a single cell cycle, both chromosome re-
arrangements and abnormal chromosome numbers that remarkably
mimic the complex genetic hallmark of tumorigenesis [59].
Conclusions
Our study demonstrates thatBRAFV600E is amore potent oncogene than
KRASG12V in transforming colon epithelial cells, whereas KRASG12V
managed to confer premature senescence to the same cell system. It
was established that BRAFV600E transformation was facilitated by the
moderate activation of pERK, as a consequence of low KSR levels,
which, however, translocated to the nucleus driving the increased pro-
liferation rate in theses cells through the hyperphosphorylation of
cyclinD1 (Figure 7A). Conversely, the sameMAPK pathway, only being
more activated, was the mediator of KRASG12V oncogene-induced se-
nescence markers and growth factor–dependent viability (Figure 7B).
Within the different biochemical properties of these two oncogenes lays
also the induction of MSI by BRAFV600E rendering Caco-2 MSI-H.
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Supplementary Materials and Methods
Protein Immunoblot Analysis and Glutathione S -Transferase
Pull-down Assay
Whole cell lysates were prepared with lysis buffer containing 50 mM
Tris-HCl (pH 7.4), 250 mM sucrose, 1 mM EDTA, 10 mM NaF,
1 mM EGTA, 1% (v/v) Triton X-100, 1 mM sodium orthovanadate,
10 μg/ml leupeptin, and 0.2 mMPMSF. Cells were lysed by swelling in
hypotonic buffer (10 mM Hepes pH 7.9, 10 mM KCl, 0.1 mM
EDTA, 0.1 mM EGTA). For Western blot analysis, protein concentra-
tions were determined by the Bradford assay (Bio-Rad Laboratories,
Hercules, CA) using bovine serum albumin as a standard. Extracts were
resolved on SDS-PAGE (10% or 12% wt/vol acrylamide), transferred
to nitrocellulose membrane (Whatman; Scheiche & Schuell, Dassel,
Germany). Antibodies used were as follows: K-Ras (sc-30), B-Raf (sc-
5284), cyclin D1 (sc-718), pTyr204 ERK (sc-7383), and α-tubulin (sc-
8035) that were purchased from Santa Cruz; pSer445 B-Raf (2696),
pSer473 Akt (9271), pSer217/221 MEK1/2 (9121), and pThr183/185
SAPK/JNK (9251) that were purchased from Cell Signaling (Danvers,
MA); cyclin E (3512-1), cyclin A (3507-1), cyclin B1 (3508-1), and
cyclin D3 (3571-1) that were purchased from Clontech (Heidelberg,
Germany); C-Raf (610151), Rb (554136), and Ral A (610221) that
were purchased from BD (Franklin Lakes, NJ); and pSer338-Raf-1
(05-538; Upstate, Lake Placid, NY).
For the glutathione S -transferase (GST) pull-down assay, 200 μg of
the identical protein extract used for Western analysis was incubated
with GST-Ral binding protein to glutathione agarose beads for 1 hour
by rotating at 4°C. Beads were washed four times in cell lysis buffer
before being loaded on 12% wt/vol SDS-PAGE. The construct was
kindly provided by Johannes L. Bos (Centre for Biomedical Gene-
tics, Utrecht, the Netherlands). Fold expression of all proteins an-
alyzed was determined after the band intensity was established using
Molecular Dynamics Image Quant Software (Amersham Biosciences,
Uppsala, Sweden).
Gene Expression RT-PCR Analysis
For RT-PCR amplification, 2.5 μl of complementary DNA tem-
plate, from all clones and control cells lines, was analyzed against dif-
ferent primers (20 pmol each) (TableW1) for a total of 25μl of reaction.
Each sample was amplified using the MJ thermocycler PTC-200 (Bio-
Rad, Hercules, CA). Intensity values were measured using Molecular
Dynamics Image Quant Software. All PCR products were normalized
to GAPDH expression.
Figure W1. RT-PCR analysis of mRNA levels for RKIP, the negative
regulator of pERK. Results were consistent among three indepen-
dent experiments.
Figure W2. RAS effector pathway Ral expression analysis and ac-
tivation by GST pull-down assay in Caco-K and Caco-BR cells. Re-
sults were consistent among three independent experiments.
Table W2. Allelic Peaks (bp).
Cell Line MSI Loci Peak 1 Peak 2 Peak 3
Caco-BR13 BAT-25 118 119
Caco-BR23 BAT-25 119 120
Caco-2 BAT-25 122 123
DLD-1 BAT-25 118 119
HCT116 BAT-25 117 118
Caco-BR13 BAT-26 107 108
Caco-BR23 BAT-26 108 109
Caco-2 BAT-26 111 112
DLD-1 BAT-26 108 109
HCT116 BAT-26 98 99
Caco-BR13 NR-21 89 90 91
Caco-BR23 NR-21 90 91 92
Caco-2 NR-21 95 96 96
DLD-1 NR-21 89 90 91
HCT116 NR-21 88 89 90
Caco-BR13 NR-22 131 132 133
Caco-BR23 NR-22 131 132 133
Caco-2 NR-22 135 136
DLD-1 NR-22 131 132 133
HCT116 NR-22 129 130 131
Caco-BR13 NR-24 119 120 121
Caco-BR23 NR-24 120 121 122
Caco-2 NR-24 124 125 126
DLD-1 NR-24 118 119 120
HCT116 NR-24 117 118 119
Table W1. Primers Used for RT-PCR.
Primers Sequence °C (No. of Cycles) Size (bp) Reference
p19Arf F: 5′-CCCTCGTGCTGATGCTACTGA-3′ 56 (35) 200 [60]
R: 5′-ACCACCAGCGTGTCCAGGAA-3′
p15Ink4b F: 5′-AGGGATATTTAGGAGTGTGTGAC-3′ 60 (30) 114 [60]
R: 5′-CCATCGGAAGATTCGTAGCC-3′
p19Ink4d F: 5′-CAGTTTGTGGCTTATAGGTG-3′ 56 (30) 101 [60]
R: 5′-CCCTTCTCTGTCCAACAC-3′
p21Cip1/Waf1 F: 5′-GGAAGACCATGTGGACCTGT-3′ 59 (32) 146 [60]
R: 5′-GGCGTTTGGAGTGGTAGAAA-3′
p27Kip1 F: 5′-CCACGAAGAGTTAACCCGGG-3′ 60 (35) 450 [60]
R: 5′-GTCTGCTCCACAGAACCGGC-3′
p57Kip2 F: 5′-CTGACCAGCTGCACTCGGGGATTTC-3′ 60 (35) 424 [60]
R: 5′-GCCGCCGGTTGCTGCTACATGA-3′
Cyclin D1 F: 5′-CTTCCTCTCCAAAATGCCAG-3′ 58 (28) 717 [60]
R: 5′-AGAGATGGAAGGGGGAAAGA-3′
Cyclin D3 F: 5′-ACTGGATGCTGGAGGTATGT-3′ 57 (35) 85 [60]
R: 5′-GACAGGTAGCGATCCAGGTA-3′
Cyclin E1 F: 5′-TGGGCAAATAGAGAGGAAGTC-3′ 58 (28) 639 [60]
R: 5′-GCACCACTGATACCCTGAA-3′
RKIP F: 5′-TCATTTCCTGGTGGTCAAC-3′ 55 (28) 133 [60]
R: 5′-CCTGTCCTGCTCGTAAAC-3′
KSR F: 5′-CCTTCCTGCCACTAACTC_3′ 56 (30) 210 [60]
R: 5′-GGGTGCTCCTTCTTTGTC-3′
Ku70 F: 5′-GATGCACCTGAAGAAACCTG-3′ 58 (30) 101 [60]
R: 5′-GATTCCTCAAAGTGAACCCT-3′
XPC F: 5′-CCCAGCCCGCTTTACCA-3′ 60 (28) 97 [60]
R:5′-TGCATTAACTGTAAATGTTCCAATGA-3′
ERCC1-variant 1 F: 5′-TGACCACATTTGGATCTCTG-3′ 114 [60]
R: 5′-CAACTCCTTGGGTTCTTTCC-3′
ERCC3 F: 5′-TGCCATTTCTAAGACTGCTG-3′ 60 (28) 123 [60]
R: 5′-TTCATCCTTGTCCATTTGCT-3′
GAPDH F: 5′-GAAGGTGAAGGTCGGAGT-3′ 58 (28) 155 [60]
R: 5′-CATGGGTGGAATCATATTGGAA-3′
